Whatever you might think about the sceptics, thus

Quote:

---

Whatever you might think about the sceptics, thus far they’ve proven being right. The share price is going down and down. Every long must be looking at ever increasing losses.

---

It is easy to be a sceptic with no skin in the game. The current share price sucks I know, everyone is red, but pre-clinical biotech, especially otc, is a bumpy ride. To view the share price as who is ultimately right or wrong at this point is a mistake. We are sitting at a 142M market cap. By the way 1100 people taking leronlimab would bring in 142M in yearly revenue at their current price. Do you think they will sign up 1100 people next year after approval?

I think leronlimab will ultimately bring in 50B+ in revenue and we will look back 10 years from now in amazement at this point in time.